These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17043838)

  • 21. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.
    Valayannopoulos V; de Blic J; Mahlaoui N; Stos B; Jaubert F; Bonnet D; Fischer A; de Lonlay P
    Pediatrics; 2010 Nov; 126(5):e1242-7. PubMed ID: 20974778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
    Wraith JE
    Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.
    Liang J; Singhal A
    J Neurosurg Pediatr; 2016 May; 17(5):537-9. PubMed ID: 26745646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.
    Grewal SS; Wynn R; Abdenur JE; Burton BK; Gharib M; Haase C; Hayashi RJ; Shenoy S; Sillence D; Tiller GE; Dudek ME; van Royen-Kerkhof A; Wraith JE; Woodard P; Young GA; Wulffraat N; Whitley CB; Peters C
    Genet Med; 2005 Feb; 7(2):143-6. PubMed ID: 15714083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
    Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
    Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
    Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
    Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
    Gabrielli O; Clarke LA; Bruni S; Coppa GV
    Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
    D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
    Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mucopolysaccharidosis I, Hurler syndrome: a case report].
    Amorín M; Carlin A; Prötzel A
    Arch Argent Pediatr; 2012 Oct; 110(5):e103-6. PubMed ID: 23070190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.
    Pitz S; Ogun O; Bajbouj M; Arash L; Schulze-Frenking G; Beck M
    Arch Ophthalmol; 2007 Oct; 125(10):1353-6. PubMed ID: 17923542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
    Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
    Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
    Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
    Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of haemopoietic stem cell transplantation on the ocular phenotype in mucopolysaccharidosis type I (Hurler).
    Javed A; Aslam T; Jones SA; Mercer J; Tyler K; Church H; Ghosh A; Wynn R; Sornalingam K; Ashworth J
    Acta Ophthalmol; 2018 Aug; 96(5):494-498. PubMed ID: 29240299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early disease progression of Hurler syndrome.
    Kiely BT; Kohler JL; Coletti HY; Poe MD; Escolar ML
    Orphanet J Rare Dis; 2017 Feb; 12(1):32. PubMed ID: 28193245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings.
    Laraway S; Breen C; Mercer J; Jones S; Wraith JE
    Mol Genet Metab; 2013 Jul; 109(3):315-6. PubMed ID: 23721889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
    J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.